key: cord-0805926-leha2848 authors: Sloane, Philip D.; Zimmerman, Sheryl title: The Impact of the COVID-19 Pandemic on Scientific Publishing date: 2021-01-28 journal: J Am Med Dir Assoc DOI: 10.1016/j.jamda.2021.01.073 sha: fce64bb9a4eee22bb2284abd469159eb0ea56c14 doc_id: 805926 cord_uid: leha2848 nan The COVID-19 pandemic hijacked not just the world of long-term care but the entire world of basic and clinical science, with unprecedented shifts in funding priorities worldwide and a boom in medical publishing, 12 accompanied by an unprecedented increase in the number of publications. 13 A PubMed search in early 2021 for papers published in the prior year identified 111,403 publications (including preprints) with a key word of COVID-19, SARS-COV-2, coronavirus, or pandemic, compared withdby way of exampled19,256 on the human immunodeficiency virus, 14,084 on Alzheimer's disease, and 11,996 on myocardial infarction. The total number of 2020 publications indexed by PubMed was more than 1.64 million, a 10% increase over 2019. As part of this rapid shift in priorities, the world of academic publishing also changed. The timeline from data collection to publication quickened, particularly for papers about COVID-19. 14 Reports about the novel coronavirus and COVID-19 disease were prioritized, with the goal of getting them into the literature as quickly as possible. 15 Reviews of COVID-19erelated papers were frequently accelerated, and the practice of providing online availability of preprints, often before final editing and author approval, became commonplace. 15 The move toward increased open access publishing accelerated as well, with many academic journals (including JAMDA) making all COVID-19erelated papers freely available online. 16 These changes in publishing, plus the continued growth of online journals (many of which are not indexed), combined with the boom in coronavirus-related research, resulted in an overall increase of published papers. 13 This accelerated pace of academic publishing has had its drawbacks. Concerns have been raised about the quality of much of the research, and that the practice of releasing preprint articles aggravates this concern. One recent article in the Journal of Medical Ethics, for example, noted that by May 2020, ClinicalTrials.gov had registered more than 1200 COVID-related trials and expressed concern that practices of good research, such as reflection on methods, quality checks by researchers and their supervisors, and robust ethics reviews, were being compromised. 17 Concerns about the quality of peer review have been raised as well, because of resource limitations from increased article submissions and reviewer stress from new clinical and at-home obligations. Such fears were bolstered by an increase in retractions of scientific studies, particularly about COVID-19. 17e19 The COVID-19 pandemic has been stressful for scientists and academic authors and affected their ongoing research efforts. Many clinical trials, particularly those involving older populations such as persons with Alzheimer's disease or residing in long-term care settings, were disrupted or terminated entirely because of concerns about safety risk for participants and research staff. 20, 21 Laboratory research suffered, too, and the work of early career investigators was noted to have been especially impacted. 22 Clinician-scientists were additionally affected because many were pressed into extra duty to assist in the pandemic response, and some became ill with the disease. Particularly impacted were women with small children, because the transition of many schools to in-home, virtual teaching and the closing of many day care centers reduced available work time. 23e25 Until 2020, JAMDA's submissions had been growing at approximately 10% to 15% per year. In 2020, we received 1658 article submissions, a 37% increase over 2019. Most (76%) of this increase consisted of papers about COVID-19. As has been the case in scientific publishing overall, publications related to this new disease have not been associated with a reduction but rather an increase in publications in other areas as well. Figure 1 displays these trends. Although impressive, JAMDA's submission increase is no greater than that experienced by many other journals, despite the disproportionate burden it has placed on long-term care populations. 12, 13 This point speaks well about the commitment of those engaged in research related to post-acute and long-term care medicine. Figure 1 indicates that 2020's noneCOVID-19 submissions (shown by the green line), were relatively similar to overall 2019 submissions (shown by the dotted line), indicating that the large volume of 2020 COVID-19 submissions (red line) supplemented rather than supplanted ongoing research, and that in 2020, the amount of noneCOVID-19 research did not change markedly compared to the previous year. Those figures are good news, because all of the issues relevant to post-acute and long-term care that existed preeCOVID-19 remained during COVID-19. One cannot help but wonder, however, the extent to which the impact of the noneCOVID-19 papers published in 2020 will be affected by the thirst for data on COVID-19 that same yeardat least in the short run. Is it any surprise that of the top 15 downloaded JAMDA articles in 2020, 13 (87%) related to COVID-19? Just as there has been concern regarding delay or avoidance of medical care due to COVID-19, 26 attention paid to other pressing needs has been postponed, which may affect citations in the short run. Researchers in many fields may be disappointed by the importance of their work being temporarily overlooked, but fortunately, the operative word is temporarily. In 2021, JAMDA will summarize some of the noneCOVID papers published during 2020 that merit renewed attention. With the increased volume and drive to process manuscripts quickly, JAMDA's editors were intent to obtain high-quality reviews at a time when our reviewersdparticularly clinician-reviewersdwere often overwhelmed by extra duties. An especially reliable reviewer wrote this as part of an apologetic decline of a review request: "I am up to my eyeballs. . I have no more bandwidth." Even getting the virus under control did not always make life easier. One trusted reviewer from a country that had finally begun to control the virus wrote the following when reminded about an overdue review: "Sincere apologies for my delay. . With the lockdown [here] coming to an end and our research activities re-starting, these times have been extremely busy." Despite the increased volume and demands on reviewers, JAMDA's metrics have remained excellent. Our average time to a first decision on a paper decreased from 22.4 days in 2019 to 17.6 days in 2020, and, for papers undergoing full review by multiple reviewers, the average time increased only slightly from 7.3 to 7.7 weeks. JAMDA's editorial team is always grateful for the time and thoughtful input of our reviewers, and especially so in 2020. We recognize the contributions of these reviewers, listed in The Appendix, during a most challenging year. A comparison of COVOD-19 mortality rates among long-term care residents in 12 OECD countries Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic Loneliness and isolation in long-term care and the COVID-19 pandemic Evaluating barriers to adopting telemedicine worldwide: A systematic review Innovation through regulation: COVID-19 and the evolving utility of telemedicine Frequently asked questions: COVID-19 testing at skilled nursing facilities/nursing homes Medicare and Medicaid programs; Reform of requirements for long-term care facilities Cruise ships, nursing homes, and prisons as COVID-19 epicenters: A "wicked problem" with breakthrough solutions? The need to include assisted living in responding to the COVID-19 pandemic COVID-19 collaborative model for an academic hospital and long-term care facilities Partnering with local hospitals and public health to manage COVID-19 outbreaks in nursing homes How science beat the virus, and what it lost in the process. The Atlantic How a torrent of COVID science changed research publishingdin seven charts Internationale wissenschaftliche Publikationsaktivität zu COVID-19 Will the pandemic permanently alter scientific publishing? Publishers make coronavirus (COVID-19) content freely available and reusable The carnage of substandard research during the COVID-19 pandemic: A call for quality Science at warp speed: Medical research, publication, and translation during the COVID-19 pandemic An alarming retraction rate for scientific publications on Coronavirus Disease 2019 (COVID-19) Ethical challenges in clinical research during the COVID-19 pandemic A modeling informed quantitative approach to salvage clinical trials interrupted due to COVID-19 COVID-19 lockdown hits young faculty and clinical trials Unequal effects of the COVID-19 pandemic on scientists The pandemic and the female academic Never seen anything like it," says one editor. The Lily. 2020. Available at: www.thelily.com/women-academics-seem-to-be-submitting-fe wer-papers-during-coronavirus-never-seen-anything-like Delay or avoidance of medical care because of COVID-19erelated concernsdUnited States The authors thank Jason Winkler, MBA